BIAL is heavily committed to developing innovative medicaments as part of its expansion strategy. The BIAL Group invests over 20% of its turnover in R&D.
Our R&D centres in Portugal and Spain are staffed by international teams of highly qualified people. They comprise chemists, pharmacologists, biochemists, physicians and pharmacists, all of whom are dedicated to finding new drugs, in three major areas of research: the central nervous system, cardiology and allergen immunotherapy. These teams centralise the initial stages that form the framework of the research process. They collaborate actively in a network of dozens of research units, firms and international institutions.
The R&D department in Porto centralizes all the areas involved in the process of finding new medicinal products: chemical, pharmacological and clinical investigation. This centre is equipped with the very latest technologies, and also has a human pharmacology unit which occupies 2 300 m2. It has 20 in-patient beds. BIAL is the only pharmaceutical laboratory in Portugal with a human pharmacology unit authorized to carry out Phase I clinical trials.
In the area of allergology, our R&D is centred in our Bilbao facility, in Spain. Work is based on biotechnological processes and has already yielded the standardization of 250 natural allergens, 33 of which are biologically standardized.
In recognition of BIAL's commitment to research and development, the group is a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA), the respected federation of leading research firms in the European pharmaceutical sector.